Microsomal transfer protein inhibition in humans

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 246-250

  Cuchel, Marina ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Homozygous familial hypercholesterolemia; Lomitapide; Microsomal triglyceride transfer protein; MTP inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; APOLIPOPROTEIN A; APOLIPOPROTEIN B; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMPLITAPIDE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; RETINOL; SIMVASTATIN; TRIACYLGLYCEROL; VITAMIN D; WARFARIN;

ABETALIPOPROTEINEMIA; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLATULENCE; HUMAN; INSULIN RESISTANCE; INTERNATIONAL NORMALIZED RATIO; LIPID STORAGE; LOW FAT DIET; MONOTHERAPY; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PRIORITY JOURNAL; RETINOL DEFICIENCY; REVIEW; SIDE EFFECT; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN D DEFICIENCY;

ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BENZIMIDAZOLES; BLOOD COMPONENT REMOVAL; CARRIER PROTEINS; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE II AS TOPIC; DIET, FAT-RESTRICTED; GENE EXPRESSION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIVER; TRIGLYCERIDES;

EID: 84880133265     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32836139df     Document Type: Review

References (43)

1. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochimic Biophys Acta 1997; 1345:136-150. (Pubitemid 27138415)
2. Kane J, Havel R. Disorders of the Biogenesis and Secretion of Lipoproteins Containing the B Apolipoproteins. In: Scriver CR, Beaudet A, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 2001. pp. 2717-2752.
3. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258:999-1001.
4. Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protien associated with abetalipoproteinemia. Nature 1993; 365:65-69. (Pubitemid 23305570)
5. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Ann Rev Nutr 2000; 20:663-697.
6. Hussain MM, Rava P, Walsh M, et al. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond) 2012; 9:14.
7. Ginsberg HN, Fisher EA. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res 2009; 50 (Suppl): S162-S166.
8. Dougan SK, Salas A, Rava P, et al. Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med 2005; 202:529-539. (Pubitemid 41186951)
9. Zeissig S, Dougan SK, Barral DC, et al. Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. J Clin Invest 2010; 120:2889-2899.
10. Jamil H, Gordon DA, Eustice DC, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci U S A 1996; 93:11991-11995. (Pubitemid 26347236)
11. Bakillah A, Nayak N, Saxena U, et al. Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist. Biochemistry 2000; 39:4892-4899. (Pubitemid 30225355)
12. Ksander G, deJesus R, Yuan A, et al. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J Med Chem 2001; 44:4677-4687. (Pubitemid 33144477)
13. Chang G, Ruggeri R, Harwood HJ. Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr Opin Drug Discov Devel 2002; 5:562-570. (Pubitemid 36748986)
14. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44:1887-1901. (Pubitemid 37356661)
15. Ueshima K, Akihisa-Umeno H, Nagayoshi A, et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005; 28: 247-252. (Pubitemid 40880003)
16. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282:751-754. (Pubitemid 28489389)
17. Shiomi M, Ito T, Harrity TW, et al. MTP inhibitor decreases plasma cholesterol levels in LDL receptordeficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001; 431:127-131. (Pubitemid 33082160)
18. Farnier M, Stein E, Megnien S et al. Efficacy and safety of implitapide, a microsomal triglyceride transfer protein inhibitor in patients with primary hypercholesterolemia [Abstract]. In: Abstract Book of the XIV International Symposium on Drug Affecting Lipid Metabolism; 9-12 September 2001; New York. p. 46.
19. Stein EA, Ames SA, Moore LJ, Isaacshon JL. Inhibition of postprandial fat absorption with the MTP inhibitor BAY-13-9952 (Abstract). Circulation 2000; 102 (Suppl II):601.
20. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5:497-505.
21. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease, 8th. New York: McGraw-Hill Information Services Company; 2001. pp. 2863-2913.
22. Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin Vasc Med 2004; 4:43-50. (Pubitemid 38393290)
23. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011; 124:2202-2207.
24. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadminis-tered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105:2469-2475. (Pubitemid 34568966)
25. Liao W, Hui TY, Young SG, Davis RA. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res 2003; 44:978-985. (Pubitemid 37279657)
26. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148-156. (Pubitemid 46089675)
27. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
28. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998-1006.
29. Lin MC, Li JJ, Wang EJ, et al. Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. Faseb J 1997; 11:1145-1152. (Pubitemid 27481438)
30. Avigan MI, Ishak KG, Gregg RE, Hoofnagle JH. Morphologic features of the liver in abetalipoproteinemia. Hepatology 1984; 4:1223-1226. (Pubitemid 15192277)
31. Dullaart RP, Speelberg B, Schuurman HJ, et al. Epitopes of apolipoprotein B-100 and B-48 in both liver and intestine. Expression and evidence for local synthesis in recessive abetalipoproteinemia. J Clin Invest 1986; 78:1397-1404. (Pubitemid 17181581)
32. Collins JC, Scheinberg IH, Giblin DR, Sternlieb I. Hepatic peroxisomal abnormalities in abetalipoproteinemia. Gastroenterology 1989; 97:766-770. (Pubitemid 19205153)
33. Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoprotei-nemia with high-dose vitamin E therapy. Can Med Assoc J1985; 132:41-44. (Pubitemid 15198682)
34. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology 1974; 67:107-118.
35. Illingworth DR, Connor WE, Miller RG. Abetalipoproteinemia. Report of two cases and review of therapy. Arch Neurol 1980; 37:659-662. (Pubitemid 10018495)
36. Braegger CP, Belli DC, Mentha G, Steinmann B. Persistence of the intestinal defect in abetalipoproteinaemia after liver transplantation. Eur J Pediatr 1998; 157:576-578. (Pubitemid 28311486)
37. Black DD, Hay RV, Rohwer-Nutter PL, et al. Intestinal and hepatic apolipo-protein B gene expression in abetalipoproteinemia. Gastroenterology 1991; 101:520-528.
38. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139:149-153.
39. Della Corte C, Fintini D, Giordano U et al. Fatty liver and insulin-resistance in children with hypobetalipoproteinemia: the importance of etiology. Clin Endocrinol 2013 [Epub ahead of print]. doi: 10.1111/j.1365-2265. 2012.04498.x
40. Buettner R, Ottinger I, Scholmerich J, Bollheimer LC. Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. Am J Physiol Endocrinol Metab 2004; 286:E828-E833. (Pubitemid 38506954)
41. Mera Y, Odani N, Kawai T, et al. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino] p henyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor ofmicrosomal triglyceride transfer protein.J Pharmacol Exp Ther 2011; 336:321-327.
42. Robinson RP, Bartlett JA, Bertinato P, et al. Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide. Bioorg Med Chem Lett 2011; 21:4150-4154.
43. Kim E, Campbell S, Schueller O, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmaco-dynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther 2011; 337:775-785.